AEON Biopharma
AEON
16 hedge funds and large institutions have $885K invested in AEON Biopharma in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 24 closing their positions.
14.19% more ownership
Funds ownership: 0.31% → 14.5% (+14%)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
57% less funds holding
Funds holding: 37 → 16 (-21)
82% less capital invested
Capital invested by funds: $4.8M → $885K (-$3.91M)
88% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
+$7.3M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$3.2M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$16.2K |
| 4 |
SS
SBI Securities
Tokyo,
Japan
|
+$748 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$36 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$1.49M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$405K |
| 3 |
FAM
Formidable Asset Management
Cincinnati,
Ohio
|
-$372K |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$139K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$136K |
AEON Hedge Fund Activity: Q1 2025 in Review
16 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q1 2025, worth a combined $885K — down 82% from $4.8M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of AEON and 3 opened new positions — a net loss of 21 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was Dauntless Investment Group, opening a new position worth an estimated $7.3M. The largest seller was Polar Asset Management Partners, exiting entirely with an estimated $1.49M sold.
- 16 institutional investors held AEON Biopharma (AEON) as of Q1 2025, down from 37 in Q4 2024.
- Funds reported $885K of AEON Biopharma stock for Q1 2025, down 82% quarter-over-quarter.
- 3 funds opened new AEON Biopharma positions in Q1 2025 and 24 closed out, a net change of -21 holders.
- The largest AEON Biopharma buyer in Q1 2025 was Dauntless Investment Group, an estimated $7.3M added.
- The largest AEON Biopharma seller in Q1 2025 was Polar Asset Management Partners, an estimated $1.49M sold.
Based on aggregated 13F filings for Q1 2025.